Degradation of AMPK-α1 sensitizes BRAF inhibitor-resistant melanoma cells to arginine deprivation

Ying Ying Li, Chunjing Wu, Sumedh S. Shah, Shu Mei Chen, Medhi Wangpaichitr, Macus T. Kuo, Lynn G. Feun, Xiaoqing Han, Miguel Suarez, Jeffrey Prince, Niramol Savaraj

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Melanomas harboring BRAF mutation (V600E) are known to recur frequently following treatment with BRAF inhibitors (BRAFi) despite a high initial response rate. Our previous study has uncovered that BRAFi-resistant melanoma (BR) cells are vulnerable to arginine deprivation. It has been reported that naïve melanoma cells undergo autophagy and re-express argininosuccinate synthetase 1 (ASS1) to enable them to synthesize arginine for survival when encountering arginine deprivation. Abolishing these two factors in BR cells confers sensitivity to arginine deprivation. In this report, we further demonstrated that downregulation of AMPK-α1 in BR cells is a major factor contributing to impairment of autophagy as evidenced by decreased autophagosome formation. These BR cells also showed a metabolic shift from glucose to arginine dependence, which was supported by decreased expressions of GLUT1 (glucose transporter) and hexokinase II (HKII) coupled with less glucose uptake but high levels of arginine transporter CAT-2 expression. Furthermore, silencing CAT-2 expression also distinctly attenuated BR cell proliferation. Notably, when naïve melanoma cells became BR cells by long-term exposure to BRAFi, a stepwise degradation of AMPK-α1 was initiated via ubiquitin-proteasome system (UPS). We discovered that a novel E3 ligase, RING finger 44 (RNF44), is responsible for promoting AMPK-α1 degradation in BR cells. RNF44 expression in BR cells was upregulated by transcription factor CREB triggered by hyperactivation of ERK/AKT. High levels of RNF44 corresponding to low levels of AMPK-α1 appeared in BR xenografts and melanoma tumor samples from BR and BRAFi/MEK inhibitor (MEKi)-resistant (BMR) melanoma patients. Similar to BR cells, BMR cells were also sensitive to arginine deprivation. Our study provides a novel insight into the mechanism whereby BRAFi or BRAFi/MEKi resistance drives proteasomal degradation of AMPK-α1 and consequently regulates autophagy and metabolic reprogramming in melanoma cells.

Original languageEnglish
Pages (from-to)1806-1825
Number of pages20
JournalMolecular Oncology
Volume11
Issue number12
DOIs
Publication statusPublished - Dec 1 2017

Fingerprint

AMP-Activated Protein Kinases
Arginine
Melanoma
Autophagy
Mitogen-Activated Protein Kinase Kinases
Cationic Amino Acid Transporter 2
Argininosuccinate Synthase
Glucose
Hexokinase
Ubiquitin-Protein Ligases
Facilitative Glucose Transport Proteins
Proteasome Endopeptidase Complex

Keywords

  • AMPK-α1
  • autophagy
  • BRAF inhibitor-resistant melanoma
  • E3 ubiquitin ligase
  • metabolic reprogramming
  • ubiquitin-proteasome system

ASJC Scopus subject areas

  • Molecular Medicine
  • Genetics
  • Oncology
  • Cancer Research

Cite this

Degradation of AMPK-α1 sensitizes BRAF inhibitor-resistant melanoma cells to arginine deprivation. / Li, Ying Ying; Wu, Chunjing; Shah, Sumedh S.; Chen, Shu Mei; Wangpaichitr, Medhi; Kuo, Macus T.; Feun, Lynn G.; Han, Xiaoqing; Suarez, Miguel; Prince, Jeffrey; Savaraj, Niramol.

In: Molecular Oncology, Vol. 11, No. 12, 01.12.2017, p. 1806-1825.

Research output: Contribution to journalArticle

Li, YY, Wu, C, Shah, SS, Chen, SM, Wangpaichitr, M, Kuo, MT, Feun, LG, Han, X, Suarez, M, Prince, J & Savaraj, N 2017, 'Degradation of AMPK-α1 sensitizes BRAF inhibitor-resistant melanoma cells to arginine deprivation', Molecular Oncology, vol. 11, no. 12, pp. 1806-1825. https://doi.org/10.1002/1878-0261.12151
Li, Ying Ying ; Wu, Chunjing ; Shah, Sumedh S. ; Chen, Shu Mei ; Wangpaichitr, Medhi ; Kuo, Macus T. ; Feun, Lynn G. ; Han, Xiaoqing ; Suarez, Miguel ; Prince, Jeffrey ; Savaraj, Niramol. / Degradation of AMPK-α1 sensitizes BRAF inhibitor-resistant melanoma cells to arginine deprivation. In: Molecular Oncology. 2017 ; Vol. 11, No. 12. pp. 1806-1825.
@article{ac13a3fc02174d16912bdf80d42f91f4,
title = "Degradation of AMPK-α1 sensitizes BRAF inhibitor-resistant melanoma cells to arginine deprivation",
abstract = "Melanomas harboring BRAF mutation (V600E) are known to recur frequently following treatment with BRAF inhibitors (BRAFi) despite a high initial response rate. Our previous study has uncovered that BRAFi-resistant melanoma (BR) cells are vulnerable to arginine deprivation. It has been reported that na{\"i}ve melanoma cells undergo autophagy and re-express argininosuccinate synthetase 1 (ASS1) to enable them to synthesize arginine for survival when encountering arginine deprivation. Abolishing these two factors in BR cells confers sensitivity to arginine deprivation. In this report, we further demonstrated that downregulation of AMPK-α1 in BR cells is a major factor contributing to impairment of autophagy as evidenced by decreased autophagosome formation. These BR cells also showed a metabolic shift from glucose to arginine dependence, which was supported by decreased expressions of GLUT1 (glucose transporter) and hexokinase II (HKII) coupled with less glucose uptake but high levels of arginine transporter CAT-2 expression. Furthermore, silencing CAT-2 expression also distinctly attenuated BR cell proliferation. Notably, when na{\"i}ve melanoma cells became BR cells by long-term exposure to BRAFi, a stepwise degradation of AMPK-α1 was initiated via ubiquitin-proteasome system (UPS). We discovered that a novel E3 ligase, RING finger 44 (RNF44), is responsible for promoting AMPK-α1 degradation in BR cells. RNF44 expression in BR cells was upregulated by transcription factor CREB triggered by hyperactivation of ERK/AKT. High levels of RNF44 corresponding to low levels of AMPK-α1 appeared in BR xenografts and melanoma tumor samples from BR and BRAFi/MEK inhibitor (MEKi)-resistant (BMR) melanoma patients. Similar to BR cells, BMR cells were also sensitive to arginine deprivation. Our study provides a novel insight into the mechanism whereby BRAFi or BRAFi/MEKi resistance drives proteasomal degradation of AMPK-α1 and consequently regulates autophagy and metabolic reprogramming in melanoma cells.",
keywords = "AMPK-α1, autophagy, BRAF inhibitor-resistant melanoma, E3 ubiquitin ligase, metabolic reprogramming, ubiquitin-proteasome system",
author = "Li, {Ying Ying} and Chunjing Wu and Shah, {Sumedh S.} and Chen, {Shu Mei} and Medhi Wangpaichitr and Kuo, {Macus T.} and Feun, {Lynn G.} and Xiaoqing Han and Miguel Suarez and Jeffrey Prince and Niramol Savaraj",
year = "2017",
month = "12",
day = "1",
doi = "10.1002/1878-0261.12151",
language = "English",
volume = "11",
pages = "1806--1825",
journal = "Molecular Oncology",
issn = "1574-7891",
publisher = "wiley",
number = "12",

}

TY - JOUR

T1 - Degradation of AMPK-α1 sensitizes BRAF inhibitor-resistant melanoma cells to arginine deprivation

AU - Li, Ying Ying

AU - Wu, Chunjing

AU - Shah, Sumedh S.

AU - Chen, Shu Mei

AU - Wangpaichitr, Medhi

AU - Kuo, Macus T.

AU - Feun, Lynn G.

AU - Han, Xiaoqing

AU - Suarez, Miguel

AU - Prince, Jeffrey

AU - Savaraj, Niramol

PY - 2017/12/1

Y1 - 2017/12/1

N2 - Melanomas harboring BRAF mutation (V600E) are known to recur frequently following treatment with BRAF inhibitors (BRAFi) despite a high initial response rate. Our previous study has uncovered that BRAFi-resistant melanoma (BR) cells are vulnerable to arginine deprivation. It has been reported that naïve melanoma cells undergo autophagy and re-express argininosuccinate synthetase 1 (ASS1) to enable them to synthesize arginine for survival when encountering arginine deprivation. Abolishing these two factors in BR cells confers sensitivity to arginine deprivation. In this report, we further demonstrated that downregulation of AMPK-α1 in BR cells is a major factor contributing to impairment of autophagy as evidenced by decreased autophagosome formation. These BR cells also showed a metabolic shift from glucose to arginine dependence, which was supported by decreased expressions of GLUT1 (glucose transporter) and hexokinase II (HKII) coupled with less glucose uptake but high levels of arginine transporter CAT-2 expression. Furthermore, silencing CAT-2 expression also distinctly attenuated BR cell proliferation. Notably, when naïve melanoma cells became BR cells by long-term exposure to BRAFi, a stepwise degradation of AMPK-α1 was initiated via ubiquitin-proteasome system (UPS). We discovered that a novel E3 ligase, RING finger 44 (RNF44), is responsible for promoting AMPK-α1 degradation in BR cells. RNF44 expression in BR cells was upregulated by transcription factor CREB triggered by hyperactivation of ERK/AKT. High levels of RNF44 corresponding to low levels of AMPK-α1 appeared in BR xenografts and melanoma tumor samples from BR and BRAFi/MEK inhibitor (MEKi)-resistant (BMR) melanoma patients. Similar to BR cells, BMR cells were also sensitive to arginine deprivation. Our study provides a novel insight into the mechanism whereby BRAFi or BRAFi/MEKi resistance drives proteasomal degradation of AMPK-α1 and consequently regulates autophagy and metabolic reprogramming in melanoma cells.

AB - Melanomas harboring BRAF mutation (V600E) are known to recur frequently following treatment with BRAF inhibitors (BRAFi) despite a high initial response rate. Our previous study has uncovered that BRAFi-resistant melanoma (BR) cells are vulnerable to arginine deprivation. It has been reported that naïve melanoma cells undergo autophagy and re-express argininosuccinate synthetase 1 (ASS1) to enable them to synthesize arginine for survival when encountering arginine deprivation. Abolishing these two factors in BR cells confers sensitivity to arginine deprivation. In this report, we further demonstrated that downregulation of AMPK-α1 in BR cells is a major factor contributing to impairment of autophagy as evidenced by decreased autophagosome formation. These BR cells also showed a metabolic shift from glucose to arginine dependence, which was supported by decreased expressions of GLUT1 (glucose transporter) and hexokinase II (HKII) coupled with less glucose uptake but high levels of arginine transporter CAT-2 expression. Furthermore, silencing CAT-2 expression also distinctly attenuated BR cell proliferation. Notably, when naïve melanoma cells became BR cells by long-term exposure to BRAFi, a stepwise degradation of AMPK-α1 was initiated via ubiquitin-proteasome system (UPS). We discovered that a novel E3 ligase, RING finger 44 (RNF44), is responsible for promoting AMPK-α1 degradation in BR cells. RNF44 expression in BR cells was upregulated by transcription factor CREB triggered by hyperactivation of ERK/AKT. High levels of RNF44 corresponding to low levels of AMPK-α1 appeared in BR xenografts and melanoma tumor samples from BR and BRAFi/MEK inhibitor (MEKi)-resistant (BMR) melanoma patients. Similar to BR cells, BMR cells were also sensitive to arginine deprivation. Our study provides a novel insight into the mechanism whereby BRAFi or BRAFi/MEKi resistance drives proteasomal degradation of AMPK-α1 and consequently regulates autophagy and metabolic reprogramming in melanoma cells.

KW - AMPK-α1

KW - autophagy

KW - BRAF inhibitor-resistant melanoma

KW - E3 ubiquitin ligase

KW - metabolic reprogramming

KW - ubiquitin-proteasome system

UR - http://www.scopus.com/inward/record.url?scp=85034019933&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85034019933&partnerID=8YFLogxK

U2 - 10.1002/1878-0261.12151

DO - 10.1002/1878-0261.12151

M3 - Article

VL - 11

SP - 1806

EP - 1825

JO - Molecular Oncology

JF - Molecular Oncology

SN - 1574-7891

IS - 12

ER -